GlassScriptPhysician profile
Daniel W Mulligan
NPI 1649257056
$531.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.64 · 2022: $216 · 2023: $270 · 2024: $22.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $129.22 | 2022-2023 | |
| Abbvie INC. | $93.38 | 2021-2023 | |
| Glaxosmithkline, LLC. | $86.10 | 2023 | Trelegy Ellipta |
| Lilly USA, LLC | $33.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.07 | 2022 | |
| Exact Sciences Corporation | $24.67 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $24.24 | 2023 | |
| Scpharmaceuticals INC. | $22.93 | 2024 | |
| Novo Nordisk INC | $21.07 | 2023 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $15.67 | 2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $15.14 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.57 | 2023 | Trulance, Xifaxan |
| Vanda Pharmaceuticals INC. | $13.37 | 2023 | Hetlioz |
| Daiichi Sankyo INC. | $13.28 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mulligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.